Therapeutic Notes

American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum 📋PharmD books📗 قناة تهتم بنشر كل المراجع العلمية وال [Guidelines ]بأحدث النسخ.. 🔍تفيدك كصيدلاني سريري ممارس أو باحث في إعداد مشاريع التخرج بالنسبة للصيدلة السريرية..      👇🏻👇🏻👇🏻👇🏻 📋PharmD books📗 ♻️𝑻𝒆𝒍𝒆𝒈𝒓𝒂𝒎: https://t.me/PharmDBKH ✅شير رابط 🔗 القناة لكي تعم الفائدة ❤️

- How to choose between beta-blockers

- How to choose between calcium channel blocker.

ACS ( HIGH- YIELD CLINICAL GUIDE)

- Meningitis (high- yield clinical guide)

PPI DRUG COMPARISON

- Sertraline vs Fluoxetine vs Paroxetine

Sertraline

2026 ACG Clinical Guideline: Hepatic Encephalopathy PharmD books📗 قناة تهتم بنشر كل المراجع العلمية وال [Guidelines ]بأحدث النسخ.. 🔍تفيدك كصيدلاني سريري ممارس أو باحث في إعداد مشاريع التخرج بالنسبة للصيدلة السريرية..      👇🏻👇🏻👇🏻👇🏻 📋PharmD books📗 ♻️𝑻𝒆𝒍𝒆𝒈𝒓𝒂𝒎: https://t.me/PharmDBKH ✅شير رابط 🔗 القناة لكي تعم الفائدة ❤️

🚨AASM 2026 Guideline: Combination Therapy for Chronic Insomnia Disorder Executive Summary (Key Takeaways) 💉CBT-I is First-Line: Multicomponent Cognitive Behavioral Therapy for Insomnia (CBT-I) remains the preferred initial treatment over combination therapy. ✅Combination > Medication Alone: In adults with chronic insomnia, concurrent CBT-I plus medication is suggested over using medication alone. ✅CBT-I Alone > Combination: For most patients, CBT-I alone is suggested over the concurrent initiation of medication and CBT-I. ✅Prioritize Sleep Time: Combination therapy may be selected if the patient prioritizes a rapid increase in Total Sleep Time (TST) early in treatment. ✅Daytime Symptoms: Patients prioritizing the reduction of daytime symptoms (fatigue, malaise) should focus on CBT-I alone, as combination therapy may show smaller improvements in these areas. ✅Avoid Sleep Hygiene Monotherapy: Sleep hygiene instructions should not be used as a standalone treatment or the sole behavioral component of combination therapy. 🧿Clinical Indications Inclusion: Adults meeting ICSD or DSM criteria for chronic insomnia (difficulty falling/staying asleep associated with daytime distress/impairment). Exclusion/Precaution: Patients with high suspicion of other sleep disorders (e.g., sleep-related breathing disorders) require objective testing before proceeding with standard insomnia protocols. 🧿Stepwise Management Initial Assessment: Clinical history to confirm chronic insomnia; screen for comorbid sleep apnea, pain, or mental health disorders. First-Line Therapy: Multicomponent CBT-I (in-person, telehealth, or FDA-cleared digital platforms). ✅Escalation/Selection of Combination: Consider concurrent initiation of CBT-I and medication if: Patient places high value on increasing TST quickly. Rapid symptom relief is the clinical priority. CBT-I is acceptable but not immediately available. ✅Medication Monotherapy: Reserved for those unable to participate in CBT-I, those with residual symptoms after CBT-I, or when CBT-I is unavailable/unaffordable. ✅Drug Therapy (Select Agents from Trial Data/AASM 2017 CPG) Note: This 2026 guideline references the 2017 pharmacological CPG for specific dosing; clinician judgment is required for adjustments. 🚨Drug Name ✅Zolpidem :Onset/Maintenance Extensively studied in combination with CBT-I. ✅Zopiclone/Eszopiclone: Onset/Maintenance Used in combination trials; consider long-term efficacy. ✅Temazepam: Onset/Maintenance Benzodiazepine receptor agonist; used in combination trials. ✅Trazodone: Maintenance (Off-label)Conditional recommendation against in 2017, but widely prescribed; used in some combination trials. ✅Doxepin /Suvorexant MaintenanceSuggested for sleep maintenance (AASM 2017). ✅Ramelteon / Zaleplon: Sleep Onset Suggested for sleep onset (AASM 2017). 🚨Special Populations ✅Cognitive Impairment: Medication monotherapy may be warranted if the patient lacks the ability to make behavioral changes required for CBT-I. 🚨Safety-Sensitive Occupations: Combination therapy may be preferred if obtaining adequate sleep duration (TST) is a high priority for occupational safety. 🚨Limited Evidence: Recommendations for diverse racial/ethnic backgrounds and comorbid medical/psychiatric conditions are limited due to small trial sample sizes. 🚨Red Flags ✅Suspected Sleep Apnea: Refer for objective sleep testing (polysomnography) if history suggests breathing disorders. ✅Severe Daytime Impairment: Act urgently if insomnia symptoms pose immediate safety risks (e.g., drowsy driving in safety-sensitive roles). Common Clinical Mistakes Relying on Sleep Hygiene: Clinicians often mistakenly use sleep hygiene instructions alone; this is proven ineffective compared to multicomponent CBT-I. Ignoring Daytime Side Effects: Overlooking increased morning sleepiness or reduced daytime symptom improvement when adding medication to CBT-I. Sequential Oversight: Failing to consider adding CBT-I to patients already on long-term medication (sequential treatment), which is likely beneficial.

2026 Systemic Treatment of Thyroid Cancer: ASCO Guideline PharmD books📗 قناة تهتم بنشر كل المراجع العلمية وال [Guidelines ]بأحدث النسخ.. 🔍تفيدك كصيدلاني سريري ممارس أو باحث في إعداد مشاريع التخرج بالنسبة للصيدلة السريرية..      👇🏻👇🏻👇🏻👇🏻 📋PharmD books📗 ♻️𝑻𝒆𝒍𝒆𝒈𝒓𝒂𝒎: https://t.me/PharmDBKH ✅شير رابط 🔗 القناة لكي تعم الفائدة ❤️

The newly released (March 2026) draft of the KDIGO Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) marks the first major paradigm shift in global acute kidney care since 2012. Here are the high-yield clinical and pharmacotherapeutic pearls from the updated framework: 1. Integration of the AKI-AKD-CKD Continuum * Closing the Conceptual Gap: The 2026 framework formally defines Acute Kidney Disease (AKD) as the critical transitional phase between AKI and Chronic Kidney Disease (CKD). It captures patients whose functional impairment or structural damage persists beyond 7 days but resolves or progresses before the 90-day diagnostic threshold for CKD. * Follow-Up Paradigm: Resolution of serum creatinine at discharge is no longer the endpoint of an AKI episode. There are stringent new recommendations for systematic post-AKI follow-up care to monitor functional trajectory, manage emergent proteinuria, and implement renoprotective strategies to mitigate long-term progression. 2. Biomarker-Enabled Diagnostics * Structural vs. Functional: Traditional functional markers (serum creatinine and urine output) are delayed indicators that often lag behind actual tissue injury. The new guidelines formally incorporate structural biomarkers (such as NGAL) into the diagnostic workflow. * Clinical Implication: This enables the identification of subclinical AKI—where acute tubular damage exists without a concurrent, measurable rise in serum creatinine—allowing for rapid intervention and nephrotoxin avoidance before critical functional nephron loss occurs. 3. Nephrotoxin Stewardship & EHR Integration * Systematized Stewardship: There is a robust new focus on comprehensive drug and nephrotoxin stewardship, establishing proactive medication management as a core pillar of AKI prevention and treatment. * Clinical Decision Support: The guidelines strongly advocate for utilizing validated risk prediction models coupled with Electronic Health Record (EHR) alerts. These systems are designed to trigger real-time medication reconciliation, prompt dynamic dose adjustments, and halt non-essential nephrotoxic agents. * Contrast-Associated AKI (CA-AKI): The update provides refined, individualized risk stratification protocols for contrast media, shifting away from universal preventative interventions toward targeted hydration and stewardship specifically for high-risk profiles. 4. Precision Fluid and Hemodynamic Management * De-resuscitation and Venous Congestion: Aggressive fluid loading is actively discouraged. The updated guidelines highlight the risk of renal venous congestion as a primary driver of AKI. Assessing venous excess (e.g., utilizing the VExUS ultrasound score) is gaining traction to guide early diuretic therapy and prevent fluid overload from physically impeding renal perfusion. * Fluid Selection: Balanced crystalloids continue to be strongly favored over 0.9% sodium chloride to prevent hyperchloremic metabolic acidosis and subsequent afferent arteriolar vasoconstriction. 5. Kidney Replacement Therapy (KRT) Kinetics * Demand-Capacity Mismatch: The decision to initiate KRT has shifted away from rigid temporal definitions ("early" vs. "late"). Initiation is now based on evaluating the mismatch between the patient's acute metabolic and fluid demands against their residual renal excretory capacity. * Dosing and Transition: The guidelines offer updated, highly specific parameters for selecting the appropriate KRT modality based on systemic hemodynamics, quantifying delivered clearance, and establishing objective criteria for safely discontinuing extracorporeal therapy as intrinsic renal function recovers.

KDIGO 2026 CLINICAL PRACTICE GUIDELINE FOR ACUTE KIDNEY INJURY (AKI)AND ACUTE KIDNEY DISEASE (AKD). PharmD books📗 قناة تهتم بنشر كل المراجع العلمية وال [Guidelines ]بأحدث النسخ.. 🔍تفيدك كصيدلاني سريري ممارس أو باحث في إعداد مشاريع التخرج بالنسبة للصيدلة السريرية..      👇🏻👇🏻👇🏻👇🏻 📋PharmD books📗 ♻️𝑻𝒆𝒍𝒆𝒈𝒓𝒂𝒎: https://t.me/PharmDBKH ✅شير رابط 🔗 القناة لكي تعم الفائدة ❤️

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia PharmD books📗 قناة تهتم بنشر كل المراجع العلمية وال [Guidelines ]بأحدث النسخ.. 🔍تفيدك كصيدلاني سريري ممارس أو باحث في إعداد مشاريع التخرج بالنسبة للصيدلة السريرية..      👇🏻👇🏻👇🏻👇🏻 📋PharmD books📗 ♻️𝑻𝒆𝒍𝒆𝒈𝒓𝒂𝒎: https://t.me/PharmDBKH ✅شير رابط 🔗 القناة لكي تعم الفائدة ❤️